US, Nov. 16 -- based Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a $ 65 million Series A financing round and emerged from stealth mode. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors included Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. CRISPR-based gene editing is one of the most important discoveries in recent years, and a critical technology for next generation therapeutic development. With the ability to edit DNA, scientists can address a whole range of diseases - but there are still hurdles to overcome such as delivery, immunogenicity, selectivity, and genomic accessibility with current technologies. To enable ...